Drug intelligence / Profile preview

PRN-002-02

Development stage: Preclinical
Lead developer: Proniras
Modality: Small Molecules
Administration: Oral

Overview

PRN-002-02 is an orally available small molecule modulator of AMPA and kainate receptors currently in preclinical development by Proniras. It is being investigated for the treatment of various central nervous system (CNS) disorders. As a modulator of ionotropic glutamate receptors, the compound is designed to regulate excitatory neurotransmission, which is frequently dysregulated in a range of neurological and psychiatric conditions. PRN-002-02 is part of a broader pipeline of glutamate receptor modulators at Proniras, serving as a preclinical candidate alongside the Phase 1 candidate PRN-002-01.

Targets

Kainate-type ionotropic glutamate receptorAMPAR (AMPA receptor)

Beyond the preview

Go deeper on PRN-002-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRN-002-02.

Explore the full profile